This paper examines the concept of 'microdosing' tirzepatide using multi-dose pens — delivering sub-labeled doses below the standard titration schedule — and considers the potential implications, risks, and unknowns of this practice.
No primary clinical trial results are reported; the paper presents conceptual and practical considerations around microdosing tirzepatide, including pharmacological, safety, and equity concerns without quantitative outcome data.
No original clinical data or trial results are provided; conclusions are based on theoretical reasoning rather than empirical evidence. The real-world impact of microdosing on efficacy and safety remains untested.
Clinicians should be cautious about off-label microdosing of tirzepatide outside established titration protocols, as the pharmacokinetic and safety profiles at sub-therapeutic doses are not well characterized. Until evidence is available, adherence to approved dosing schedules is advisable.
Explore related topics
